##  [How Will NMPA’s 2025 eCTD Update Impact Your Product Launch Timeline?](/index%2ephp/blog/how-will-nmpas-2025-ectd-update-impact-your-product-launch-timeline) 

    August 29, 2025 

  ![How Will NMPA’s 2025 eCTD Update Impact Your Product Launch Timeline?]()

2 min read 

- [Medicinal Products](/index%2ephp/blog-main-categories/medicinal-products)
- [Regulatory Affairs](/index%2ephp/blog-main-categories/regulatory-affairs)





 

**Beijing, January 23, 2025** — In a decisive move to advance digital Regulatory practices, the **National Medical Products Administration (NMPA)** has announced the **expansion of the Electronic Common Technical Document (eCTD)** implementation for **medicinal product submissions** in China. Effective **January 27, 2025**, this update—issued under **Announcement No.10, 2025**—represents a major step toward streamlining the drug registration lifecycle and modernizing the Regulatory environment for pharmaceuticals.

This expansion builds on the groundwork laid by **NMPA Announcement No.119, 2021**, and aligns with the country’s strategic initiative to integrate “**Internet + Drug Regulation**” into its Regulatory infrastructure.

## What Does the Expansion Cover?

The updated scope mandates that eCTD-format submissions be adopted for the following **medicinal product categories**:

**Chemical Drugs**

- **Clinical Trial Applications** for: 
    - **Class 1 to 5 chemical drugs**
- **Marketing Authorization Applications (MAA)** for: 
    - **Class 2, 3, 4, and 5.2 chemical drugs**

**Biological Products**

- **Clinical Trial Applications** for: 
    - **Class 1 to 3 preventive biological products**
    - **Class 1 to 3 therapeutic biological products**
- **Marketing Authorization Applications** for: 
    - **Class 2 and 3 biological products**

This means that from early 2025, all pharmaceutical companies submitting **new clinical or marketing applications** for a broad range of medicinal products—both chemical and biologic—must adopt the eCTD format as per China’s latest Regulatory requirements.

##  Submission Requirements for Pharmaceutical Companies

To ensure compliance, applicants must:

- Prepare and submit **eCTD-compliant electronic dossiers** that meet the latest **NMPA/CDE technical specifications**
- Preferably use **online transmission systems** for electronic submission

The “Notice on Pilot Implementation of Online Transmission for Drug Registration Electronic Application Dossier Submission”, available on the CDE website, provides detailed guidance.

## Why This Matters for Drug Developers

The eCTD expansion represents more than a formatting change—it’s a significant enabler for:

- **Accelerated application processing and review timelines**
- **Greater consistency and standardization** across Regulatory dossiers
- Enhanced collaboration and communication with Regulatory authorities
- Improved **traceability and lifecycle management** for medicinal product data

The shift aligns China’s Regulatory processes with **ICH M4 standards**, making it easier for global companies to plan simultaneous or sequential filings in China alongside other regulated markets.

## Toward a Fully Digital Regulatory Framework

China's commitment to expanding eCTD reflects a broader goal: building a **digitally integrated Regulatory ecosystem**. This initiative supports:

- **Efficiency and transparency** in the drug approval process
- Integration of **pharmacovigilance, change control, and post-marketing data**
- Readiness for **future AI-enabled Regulatory tools and automation**

For medicinal product sponsors, this signals a new baseline: **manual or paper-based dossiers will soon be outdated**.

### **Final Thoughts**

The NMPA’s expanded eCTD mandate is a critical milestone in China’s journey toward global Regulatory harmonization. For pharmaceutical companies seeking to submit **clinical trial or marketing authorization applications for medicinal products**, eCTD is now the **standard submission format**, not a future consideration.

With the scope now including **preventive and therapeutic biologics** and **non-innovator chemical drugs**, companies must act swiftly to align their documentation systems, workflows, and publishing tools.

### **Need support with eCTD dossier preparation or submission in China?**

Freyr’s global Regulatory experts help life sciences companies navigate NMPA’s eCTD compliance requirements—from dossier authoring and publishing to lifecycle management and online transmission.

[**Contact us**](javascript:void(0)) to simplify your next medicinal product submission to the Chinese market.